Recent systematic reviews and meta-analyses demonstrate that in NAFLD-NASH patient populations, statins not only significantly improve total cholesterol levels [28] but also liver enzymes including ALT and AST [25,26,28]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.